List of Xiidra drug patents
Xiidra is owned by Novartis.
Xiidra contains Lifitegrast.
Xiidra has a total of 16 drug patents out of which 0 drug patents have expired.
Xiidra was authorised for market use on 11 July, 2016.
Xiidra is available in solution/drops;ophthalmic dosage forms.
Xiidra can be used as treatment of signs and symptoms of dry eye disease (ded), treatment of the signs and symptoms of dry eye disease (ded).
The generics of Xiidra are possible to be released after 18 December, 2033.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7928122 | NOVARTIS | Modulators of cellular adhesion |
Nov, 2024
(1 year, 7 months from now) | |
| US7745460 | NOVARTIS | Modulators of cellular adhesion |
Nov, 2024
(1 year, 7 months from now) | |
| US7314938 | NOVARTIS | Modulators of cellular adhesion |
Mar, 2025
(1 year, 11 months from now) | |
| US8084047 | NOVARTIS | Compositions and methods for treatment of eye disorders |
May, 2026
(3 years from now) | |
| US9890141 | NOVARTIS | Crystalline pharmaceutical and methods of preparation and use thereof |
Oct, 2030
(7 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7790743 | NOVARTIS | Modulators of cellular adhesion |
Nov, 2024
(1 year, 7 months from now) | |
| US9216174 | NOVARTIS | Modulators of cellular adhesion |
Nov, 2024
(1 year, 7 months from now) | |
| US10124000 | NOVARTIS | Modulators of cellular adhesion |
Nov, 2024
(1 year, 7 months from now) | |
| US8592450 | NOVARTIS | Compositions and methods for treatment of eye disorders |
May, 2026
(3 years from now) | |
| US9447077 | NOVARTIS | Crystalline pharmaceutical and methods of preparation and use thereof |
Apr, 2029
(6 years from now) | |
| US8367701 | NOVARTIS | Crystalline pharmaceutical and methods of preparation and use thereof |
Apr, 2029
(6 years from now) | |
| US8168655 | NOVARTIS | Compositions and methods for treatment of eye disorders |
May, 2029
(6 years from now) | |
| US9353088 | NOVARTIS | Crystalline pharmaceutical and methods of preparation and use thereof |
Oct, 2030
(7 years from now) | |
| US8927574 | NOVARTIS | Crystalline pharmaceutical and methods of preparation and use thereof |
Nov, 2030
(7 years from now) | |
| US9085553 | NOVARTIS | LFA-1 inhibitor and methods of preparation and polymorph thereof |
Jul, 2033
(10 years from now) | |
| US11058677 | NOVARTIS | LFA-1 inhibitor formulations |
Dec, 2033
(10 years from now) | |
Drugs and Companies using LIFITEGRAST ingredient
Market Authorisation Date: 11 July, 2016
Treatment: Treatment of signs and symptoms of dry eye disease (ded); Treatment of the signs and symptoms of dry eye disease (ded)
Dosage: SOLUTION/DROPS;OPHTHALMIC
XIIDRA family patents
103
United States
30
Japan
15
European Union
12
China
9
Canada
8
Australia
7
Spain
6
Hong Kong
5
Mexico
4
Portugal
4
Slovenia
4
Poland
4
Denmark
3
Korea, Republic of
3
Cyprus
2
Russia
2
Brazil
2
EA
2
South Africa
2
Hungary
1
New Zealand
1
Austria
1
India
1
Lithuania
1
Israel
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic